The inoculum in this B-ALL xenograft model was a mixture of 1% CD19− or CD22− B-ALL with 99% wild-type cells (CD19+/CD22+), which mimics relapse from a small pre-existent clone as observed in clinical trials. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.